title: Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
abstract: We present the case of a patient with rapidly accelerated fibrosarcoma gene F (BRAF) mutated adenocarcinoma of the lung, responding to BRAF inhibitor dabrafenib after progressing on vemurafenib followed by docetaxel. The present case illustrates the potential benefit of successful rechallenge with a BRAF inhibitor, a well known phenomenon observed in other oncogenic driven molecular subtypes of non-small cell lung cancer (NSCLC) such as epidermal growth factor receptor mutation. Rechallenge with a BRAF inhibitor in BRAF mutated NSCLC should be considered, particularly in the absence of alternative therpateutic options.
authors.affiliation: Medical Oncology, Cantonal Hospital St. Gallen, Switzerland. Electronic address: sabine.schmid@kssg.ch.
authors.forename: S
authors.initials: S
authors.lastname: Schmid
authors.affiliation: Medical Oncology, Cantonal Hospital St. Gallen, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Siano
authors.affiliation: Medical Oncology, Cantonal Hospital St. Gallen, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Joerger
authors.affiliation: Pathology, Cantonal Hospital St. Gallen, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Rodriguez
authors.affiliation: Nuclear Medicine, Cantonal Hospital St. Gallen, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Müller
authors.affiliation: Medical Oncology, Cantonal Hospital St. Gallen, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Früh
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D004252:DNA Mutational Analysis; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D010091:Oximes / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics*; D019233:Retreatment; D013449:Sulfonamides / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib
keywords: Adenocarcinoma; BRAF mutation; Lung; NSCLC; Rechallenge; Resistance